Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2022 16:00

RNS Number : 9118D
ReNeuron Group plc
07 March 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BF5G6K95

Issuer Name

RENEURON GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.734800

3.035000

3.769800

2151158

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BF5G6K95

419300

0.734800

Sub Total 8.A

419300

0.734800%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

1731858

3.035000

Sub Total 8.B1

1731858

3.035000%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASDXESPAEFA
Date   Source Headline
3rd Jan 20127:00 amRNSData confirms pre-clinical efficacy of ReN001
19th Dec 20114:41 pmRNSSecond Price Monitoring Extn
19th Dec 20114:35 pmRNSPrice Monitoring Extension
6th Dec 201110:00 amRNSWelcomes UK Government Life Sciences Strategy
30th Nov 20114:35 pmRNSPrice Monitoring Extension
28th Nov 20117:00 amRNSStroke Update
28th Nov 20117:00 amRNSInterim Results
9th Nov 20117:00 amRNSStroke clinical trial update & notice of results
3rd Nov 20112:54 pmRNSNotification of Major Interest in Shares
1st Nov 20112:13 pmRNSNotification of Interest in Shares
31st Oct 201110:42 amRNSNotification of Major Interest in Shares
22nd Sep 201112:53 pmRNSDirectors' Interest in Shares and Share Options
22nd Sep 201112:48 pmRNSDirectors' Interest in Shares
15th Sep 201110:45 amRNSResults of 2011 Annual General Meeting
15th Sep 20117:00 amRNSAGM Trading Update
1st Sep 20114:35 pmRNSPrice Monitoring Extension
1st Sep 20117:00 amRNSReNeuron receives DSMB clearance
29th Jul 20113:24 pmRNSAnnual Report and Accounts and Notice of AGM
20th Jul 20117:00 amRNSBoard Appointments
5th Jul 20117:00 amRNSContract with Angel Biotechnology Holdings plc
5th Jul 20117:00 amRNSAngel signs new contract with ReNeuron
30th Jun 20117:00 amRNSPreliminary Results
24th Jun 20112:56 pmRNSReNeuron launches new website
16th Jun 20117:00 amRNSLicense agreement with US eye research institute
1st Jun 20119:43 amRNSBlock Listing Six Monthly Review
27th May 20117:00 amRNSNotice of Results and Stroke Clinical Trial Update
28th Apr 201112:22 pmRNSEU legal opinion
8th Apr 20117:00 amRNSManufacturing Agreement
28th Jan 20117:00 amRNSSettlement with Neuralstem, Inc
10th Jan 20112:18 pmRNSTR-1 Notification of major interest in shares
10th Jan 20117:00 amRNSTR-1 Notification of major interest in shares
7th Jan 20117:00 amRNSTR-1: Notification of major interest in shares
4th Jan 20117:00 amRNSMajor Interest in Shares
29th Dec 201011:34 amRNSRESULT OF GENERAL MEETING & THIRD ADMISSION
21st Dec 20107:00 amRNSUpdate on clinical trial
20th Dec 20108:01 amRNSSECOND ADMISSION
17th Dec 20108:01 amRNSFIRST ADMISSION
13th Dec 20107:01 amRNSInterim Results
13th Dec 20107:00 amRNS£10 million Fundraising
1st Dec 20107:00 amRNSBlock Listing Six Monthly Review
17th Nov 20104:41 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
17th Nov 20107:00 amRNSProgress update on ReN009
16th Nov 20107:00 amRNSFirst Patient Treated with ReN001
27th Oct 20107:00 amRNSReNeuron at stem cell and neuroscience conferences
8th Oct 201010:26 amRNS18th Annual BioPartnering Europe conference
8th Sep 201011:07 amRNSResults of 2010 Annual General Meeting
8th Sep 20107:00 amRNS2010 AGM Trading Update
9th Aug 20107:00 amRNSPosting of Report and Accounts and AGM date
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.